<?xml version='1.0' encoding='utf-8'?>
<document id="31692269"><sentence text="Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men."><entity charOffset="80-89" id="DDI-PubMed.31692269.s1.e0" text="tenofovir" /><entity charOffset="94-107" id="DDI-PubMed.31692269.s1.e1" text="emtricitabine" /><entity charOffset="140-149" id="DDI-PubMed.31692269.s1.e2" text="oestrogen" /><pair ddi="false" e1="DDI-PubMed.31692269.s1.e0" e2="DDI-PubMed.31692269.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s1.e0" e2="DDI-PubMed.31692269.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s1.e0" e2="DDI-PubMed.31692269.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s1.e1" e2="DDI-PubMed.31692269.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s1.e1" e2="DDI-PubMed.31692269.s1.e2" /></sentence><sentence text="Oral HIV Pre-Exposure Prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) is highly effective"><entity charOffset="46-55" id="DDI-PubMed.31692269.s2.e0" text="tenofovir" /><entity charOffset="62-81" id="DDI-PubMed.31692269.s2.e1" text="disoproxil fumarate" /><entity charOffset="83-86" id="DDI-PubMed.31692269.s2.e2" text="TDF" /><entity charOffset="88-101" id="DDI-PubMed.31692269.s2.e3" text="emtricitabine" /><entity charOffset="103-106" id="DDI-PubMed.31692269.s2.e4" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e0" e2="DDI-PubMed.31692269.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e0" e2="DDI-PubMed.31692269.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e0" e2="DDI-PubMed.31692269.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e0" e2="DDI-PubMed.31692269.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e0" e2="DDI-PubMed.31692269.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e1" e2="DDI-PubMed.31692269.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e1" e2="DDI-PubMed.31692269.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e1" e2="DDI-PubMed.31692269.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e1" e2="DDI-PubMed.31692269.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e2" e2="DDI-PubMed.31692269.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e2" e2="DDI-PubMed.31692269.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e2" e2="DDI-PubMed.31692269.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e3" e2="DDI-PubMed.31692269.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31692269.s2.e3" e2="DDI-PubMed.31692269.s2.e4" /></sentence><sentence text=" Transgender women (TGW) have increased HIV risk, but have been underrepresented in trials" /><sentence text=" For TGW on oestrogens for gender-affirming hormone treatment (GAHT), TDF/FTC-oestrogen interactions may negatively affect HIV prevention or gender-affirming goals"><entity charOffset="12-22" id="DDI-PubMed.31692269.s4.e0" text="oestrogens" /><entity charOffset="70-79" id="DDI-PubMed.31692269.s4.e1" text="TDF" /><entity charOffset="74-83" id="DDI-PubMed.31692269.s4.e2" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31692269.s4.e0" e2="DDI-PubMed.31692269.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s4.e0" e2="DDI-PubMed.31692269.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s4.e0" e2="DDI-PubMed.31692269.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s4.e1" e2="DDI-PubMed.31692269.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s4.e1" e2="DDI-PubMed.31692269.s4.e2" /></sentence><sentence text=" Our aim was to evaluate any pharmacokinetic drug-drug interaction between GAHT and TDF/FTC"><entity charOffset="84-86" id="DDI-PubMed.31692269.s5.e0" text="TDF" /><entity charOffset="88-90" id="DDI-PubMed.31692269.s5.e1" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31692269.s5.e0" e2="DDI-PubMed.31692269.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s5.e0" e2="DDI-PubMed.31692269.s5.e1" /></sentence><sentence text="" /><sentence text="We performed a pharmacokinetic study, in an urban outpatient setting in 2016 to 2018, of the effects of GAHT on TFV, FTC and the active forms TFV diphosphate (TFV-DP) and FTC triphosphate (FTC-TP) in eight TGW and eight cisgender men (CGM)"><entity charOffset="171-187" id="DDI-PubMed.31692269.s7.e0" text="FTC triphosphate" /><entity charOffset="189-195" id="DDI-PubMed.31692269.s7.e1" text="FTC-TP" /><entity charOffset="117-122" id="DDI-PubMed.31692269.s7.e2" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31692269.s7.e2" e2="DDI-PubMed.31692269.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s7.e2" e2="DDI-PubMed.31692269.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s7.e2" e2="DDI-PubMed.31692269.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s7.e0" e2="DDI-PubMed.31692269.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s7.e0" e2="DDI-PubMed.31692269.s7.e1" /></sentence><sentence text=" At screening, participants were HIV negative" /><sentence text=" TGW were to maintain their GAHT regimens and have plasma oestradiol concentrations &gt;100 pg/mL"><entity charOffset="58-68" id="DDI-PubMed.31692269.s9.e0" text="oestradiol" /></sentence><sentence text=" Under direct observation, participants took oral TDF/FTC daily for seven days"><entity charOffset="50-59" id="DDI-PubMed.31692269.s10.e0" text="TDF" /><entity charOffset="54-63" id="DDI-PubMed.31692269.s10.e1" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31692269.s10.e0" e2="DDI-PubMed.31692269.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s10.e0" e2="DDI-PubMed.31692269.s10.e1" /></sentence><sentence text=" At the last dose, blood was collected pre-dose, one, two, four, six, eight and twenty-four hours, and colon biopsies were collected at 24 hours to measure drug concentration" /><sentence text=" TGW versus CGM concentration comparisons used non-parametric tests" /><sentence text=" Blood and colon tissue were also obtained to assess kinase expression" /><sentence text="" /><sentence text="Plasma TFV and FTC C24 (trough) concentrations in TGW were lower by 32% (p = 0"><entity charOffset="15-17" id="DDI-PubMed.31692269.s15.e0" text="FTC" /></sentence><sentence text="010) and 32% (p = 0" /><sentence text="038) respectively, when compared to CGM" /><sentence text=" Plasma TFV and FTC 24-hr area under the concentration-time curve in TGW trended toward and was significantly lower by 27% (p = 0"><entity charOffset="16-18" id="DDI-PubMed.31692269.s18.e0" text="FTC" /></sentence><sentence text="065) and 24% (p = 0" /><sentence text="028) respectively" /><sentence text=" Peak plasma TFV and FTC concentrations, as well as all other pharmacokinetic measures, were not statistically significant when comparing TGW to CGM"><entity charOffset="21-23" id="DDI-PubMed.31692269.s21.e0" text="FTC" /></sentence><sentence text=" Oestradiol concentrations were not different comparing before and after TDF/FTC dosing"><entity charOffset="1-11" id="DDI-PubMed.31692269.s22.e0" text="Oestradiol" /><entity charOffset="73-82" id="DDI-PubMed.31692269.s22.e1" text="TDF" /><entity charOffset="77-86" id="DDI-PubMed.31692269.s22.e2" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31692269.s22.e0" e2="DDI-PubMed.31692269.s22.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s22.e0" e2="DDI-PubMed.31692269.s22.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s22.e0" e2="DDI-PubMed.31692269.s22.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s22.e1" e2="DDI-PubMed.31692269.s22.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s22.e1" e2="DDI-PubMed.31692269.s22.e2" /></sentence><sentence text=" Plasma oestrogen concentration, renal function (estimated creatinine clearance and glomerular filtration rate), and TFV and FTC plasma concentrations (trough and area under the concentration-time curve) were all correlated"><entity charOffset="8-17" id="DDI-PubMed.31692269.s23.e0" text="oestrogen" /><entity charOffset="59-69" id="DDI-PubMed.31692269.s23.e1" text="creatinine" /><entity charOffset="125-134" id="DDI-PubMed.31692269.s23.e2" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31692269.s23.e0" e2="DDI-PubMed.31692269.s23.e0" /><pair ddi="false" e1="DDI-PubMed.31692269.s23.e0" e2="DDI-PubMed.31692269.s23.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s23.e0" e2="DDI-PubMed.31692269.s23.e2" /><pair ddi="false" e1="DDI-PubMed.31692269.s23.e1" e2="DDI-PubMed.31692269.s23.e1" /><pair ddi="false" e1="DDI-PubMed.31692269.s23.e1" e2="DDI-PubMed.31692269.s23.e2" /></sentence><sentence text="" /><sentence text="GAHT modestly reduces both TFV and FTC plasma concentrations"><entity charOffset="35-37" id="DDI-PubMed.31692269.s25.e0" text="FTC" /></sentence><sentence text=" In TGW taking GAHT, it is unknown if this reduction will impact the HIV protective efficacy of a daily PrEP regimen" /><sentence text=" However, the combination of an on demand (2 + 1 + 1) PrEP regimen and GAHT may result in concentrations too low for reliable prevention of HIV infection" /><sentence text="" /></document>